- Home
- MRUS vs SPR Comparison
MRUS vs SPR Comparison
Compare MRUS & SPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRUS
- SPR
- Stock Information
- Founded
- MRUS 2003
- SPR 1927
- Country
- MRUS Netherlands
- SPR United States
- Employees
- MRUS N/A
- SPR N/A
- Industry
- MRUS Biotechnology: Pharmaceutical Preparations
- SPR Military/Government/Technical
- Sector
- MRUS Health Care
- SPR Industrials
- Exchange
- MRUS Nasdaq
- SPR Nasdaq
- Market Cap
- MRUS 5.1B
- SPR 4.8B
- IPO Year
- MRUS 2016
- SPR 2006
- Fundamental
- Price
- MRUS $94.38
- SPR $38.96
- Analyst Decision
- MRUS Buy
- SPR Hold
- Analyst Count
- MRUS 18
- SPR 2
- Target Price
- MRUS $93.72
- SPR $38.63
- AVG Volume (30 Days)
- MRUS 4.2M
- SPR 973.0K
- Earning Date
- MRUS 10-30-2025
- SPR 10-22-2025
- Dividend Yield
- MRUS N/A
- SPR N/A
- EPS Growth
- MRUS N/A
- SPR N/A
- EPS
- MRUS N/A
- SPR N/A
- Revenue
- MRUS $56,228,000.00
- SPR $6,278,800,000.00
- Revenue This Year
- MRUS $47.25
- SPR $21.25
- Revenue Next Year
- MRUS N/A
- SPR $16.36
- P/E Ratio
- MRUS N/A
- SPR N/A
- Revenue Growth
- MRUS 59.77
- SPR N/A
- 52 Week Low
- MRUS $33.19
- SPR $27.00
- 52 Week High
- MRUS $94.56
- SPR $42.33
- Technical
- Relative Strength Index (RSI)
- MRUS 86.13
- SPR 47.13
- Support Level
- MRUS $66.13
- SPR $38.11
- Resistance Level
- MRUS $94.45
- SPR $40.41
- Average True Range (ATR)
- MRUS 1.00
- SPR 0.80
- MACD
- MRUS 1.49
- SPR 0.14
- Stochastic Oscillator
- MRUS 99.38
- SPR 41.53
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
About SPR Spirit Aerosystems Holdings Inc.
Spirit AeroSystems manufactures aerostructures, particularly fuselages, cockpits, wing sections, engine pylons, and nacelles for commercial and military aircraft. The company was spun out of Boeing in 2005 to become the largest independent supplier of aerostructures for commercial aircraft. Boeing and Airbus are the firm's primary customers—Boeing represented roughly 60% and Airbus roughly 20% of revenue in recent years. The company is highly exposed to Boeing's beleaguered 737 program, which accounts for nearly half the company's revenue. The company plans to be acquired by and reintegrated into Boeing by the end of 2025.